WHY COLLECT REAL WORLD DATA IN AN EXPANDED ACCESS PROGRAM?

Expanded Access Programs (EAPs) provide sponsors the opportunity to collect meaningful Real World Data (RWD), i.e. data on health care that is derived from multiple sources outside of the typical clinical research settings.

More and more, regulatory bodies around the world, like the US Food and Drug Administration (FDA), European Medicines Agency (EMA) and the Australian Therapeutic Goods Administration (TGA), etc. are encouraging companies to collect RWD, if and when appropriate. These regulators recognize the tremendous value in collecting data in the real world setting and using it to better inform stakeholders and promote safe and effective use of products, quicker, for patients in need.

WEP Clinical has developed some slides to help companies better understand RWD collection in the expanded access space.

The slides will explore the following:

  • What is RWD

  • Sponsor and HCPs Considerations

  • Why collect RWD in EAPs

  • Types of data to collect

  • Regulations and examples

  • Regulations and examples

  • EDC system capabilities

To find out more about our RWD collection capabilities, please contact us using the email address below:

download policy templates

Please provide your name and email address in the fields below and press the download button. You should then receive the template as a pdf in a new tab in your browser. You will also receive a link to the template in your email inbox, so you can access it again later.

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    NEED MORE INFORMATION?